Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 22, 2016Journal of Crohn s and ColitisOpen Access

Switching from Remicade® to Remsima® is well tolerated and feasible: a prospective, open-label study

View Full Paper
Ask AI
Bookmark
Share

Authors

LBL. BuerOslo University HospitalBMBjørn MoumUniversity of OsloMCMilada CvancarovaOsloMet – Oslo Metropolitan University

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Buer et al. (2016) studied this question.

synapsesocial.com/papers/6a8308f5b15ea8a8ea4ccd9dhttps://doi.org/10.1093/ecco-jcc/jjw166
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1The temporal evolution of antidrug antibodies in patients with inflammatory bowel disease treated with infliximab2013 · 303 citations
  2. 2Harmonization of Infliximab and Anti-Infliximab Assays Facilitates the Comparison Between Originators and Biosimilars in Clinical Samples2016 · 46 citations
  3. 3Clinical Outcomes Following a Switch from Remicade® to the Biosimilar CT-P13 in Inflammatory Bowel Disease Patients: A Prospective Observational Cohort Study2016 · 140 citations
  4. 4Efficacy and Safety of the Biosimilar Infliximab CT-P13 Treatment in Inflammatory Bowel Diseases: A Prospective, Multicentre, Nationwide Cohort2015 · 183 citations
  5. 5Biosimilar infliximab (CT-P13) in the treatment of inflammatory bowel disease: A Norwegian observational study2015 · 112 citations